Lexeo Therapeutics (LXEO) Expected to Announce Quarterly Earnings on Monday

Key Points

• Q1 2026 earnings: Lexeo is set to report before the open on May 11, with analysts forecasting EPS of ($0.29) and an earnings call scheduled for May 13 at 9:30 AM ET.
• CEO Richard Nolan Townsend sold 55,000 shares on April 6 under a pre-arranged Rule 10b5-1 plan, reducing his ownership by 13.92%; insiders have sold 68,189 shares in the past 90 days and hold 5.30% of the stock.
• Analysts hold a consensus "Moderate Buy" with an average price target of $18.88; Lexeo has a market cap of $460.13M and a 52‑week range of $2.43–$10.99.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) is projected to release its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect Lexeo Therapeutics to post earnings of ($0.29) per share for the quarter. Interested persons can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 9:30 AM ET.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last announced its earnings results on Monday, March 30th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.32) by $0.05. On average, analysts expect Lexeo Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lexeo Therapeutics Price Performance

Shares of LXEO stock traded up $0.09 during trading hours on Monday, reaching $5.86. 38,831 shares of the company were exchanged, compared to its average volume of 977,768. Lexeo Therapeutics has a fifty-two week low of $2.43 and a fifty-two week high of $10.99. The stock's fifty day moving average is $6.29 and its two-hundred day moving average is $7.89. The company has a market cap of $460.13 million, a price-to-earnings ratio of -2.67 and a beta of 1.52.

Insider Buying and Selling at Lexeo Therapeutics

In related news, CEO Richard Nolan Townsend sold 55,000 shares of the business's stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $5.69, for a total transaction of $312,950.00. Following the completion of the sale, the chief executive officer directly owned 340,106 shares of the company's stock, valued at $1,935,203.14. The trade was a 13.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 68,189 shares of company stock worth $397,156 over the last ninety days. Insiders own 5.30% of the company's stock.

Institutional Investors Weigh In On Lexeo Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Bank of America Corp DE increased its stake in Lexeo Therapeutics by 6.1% in the third quarter. Bank of America Corp DE now owns 28,279 shares of the company's stock valued at $188,000 after purchasing an additional 1,626 shares in the last quarter. AQR Capital Management LLC increased its stake in Lexeo Therapeutics by 370.0% in the first quarter. AQR Capital Management LLC now owns 50,337 shares of the company's stock valued at $175,000 after purchasing an additional 39,627 shares in the last quarter. Police & Firemen s Retirement System of New Jersey increased its stake in Lexeo Therapeutics by 171.1% in the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 16,373 shares of the company's stock valued at $163,000 after purchasing an additional 10,333 shares in the last quarter. Persistent Asset Partners Ltd bought a new stake in Lexeo Therapeutics in the fourth quarter valued at approximately $159,000. Finally, Intech Investment Management LLC increased its stake in Lexeo Therapeutics by 19.5% in the fourth quarter. Intech Investment Management LLC now owns 14,188 shares of the company's stock valued at $141,000 after purchasing an additional 2,317 shares in the last quarter. 60.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on LXEO. Wall Street Zen lowered shares of Lexeo Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday. HC Wainwright reduced their target price on shares of Lexeo Therapeutics from $13.00 to $10.00 and set a "buy" rating on the stock in a research report on Tuesday, January 13th. Weiss Ratings lowered shares of Lexeo Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday. Finally, Chardan Capital reissued a "buy" rating and set a $17.00 price target on shares of Lexeo Therapeutics in a research note on Tuesday, January 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Lexeo Therapeutics has an average rating of "Moderate Buy" and an average price target of $18.88.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.